T1	Participants 68 101	patients with Parkinson's disease
T2	Participants 242 289	two groups of patients with Parkinson's disease
T3	Participants 291 517	The first group was composed of 10 patients with a moderate motor impairment insufficiently controlled by monotherapy with bromocriptine. The second group was composed of eight patients with L-dopa-induced peak-dose dyskinesia
T4	Participants 774 793	Parkinson's disease
